Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cellular and Molecular Biology

PSA screening in high-risk groups: what are the changes in benefits and harm?

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. McHugh J, Saunders EJ, Dadaev T, McGrowder E, Bancroft E, Kote-Jarai Z, et al. Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. Br J Cancer. 2022;126:1366–73. https://doi.org/10.1038/s41416-021-01669-3

    Article  PubMed  Google Scholar 

  2. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901–13. https://doi.org/10.1001/jama.2018.3710

    Article  Google Scholar 

  3. Takahashi T. Would you play a Russian Roulette-type game of prostate-specific antigen screening on yourself? Eur Urol. 2022;81:e22.

    Article  Google Scholar 

  4. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15:e234–42. https://doi.org/10.1016/S1470-2045(13)70598-9

    Article  PubMed  PubMed Central  Google Scholar 

  5. Young RH, Eble JN. The history of urologic pathology: an overview. Histopathology. 2019;74:184–212.

    Article  Google Scholar 

  6. Totten RS. Some experiences with latent carcinoma of the prostate. Bull N Y Acad Med. 1953;29:579–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Aronowitz R. "Screening" for prostate cancer in New York’s skid row: history and implications. Am J Public Health. 2014;104:70–6.

    Article  Google Scholar 

  8. Humphrey PA. Histopathology of prostate cancer. Cold Spring Harb Perspect Med. 2017;7:a030411.

    Article  Google Scholar 

  9. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109–18. https://doi.org/10.1200/JCO.2004.11.514

    Article  PubMed  Google Scholar 

  10. Schellhammer PF. A urologist’s personal view of prostate cancer. Turk J Urol. 2016;42:121–6. https://doi.org/10.5152/tud.2016.50318.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takeshi Takahashi.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Takahashi, T. PSA screening in high-risk groups: what are the changes in benefits and harm?. Br J Cancer 127, 1173–1174 (2022). https://doi.org/10.1038/s41416-022-01947-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-01947-8

Search

Quick links